These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28543053)

  • 1. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.
    Wirth S; Rosenthal P; Gonzalez-Peralta RP; Jonas MM; Balistreri WF; Lin CH; Hardikar W; Kersey K; Massetto B; Kanwar B; Brainard DM; Shao J; Svarovskaia E; Kirby B; Arnon R; Murray KF; Schwarz KB
    Hepatology; 2017 Oct; 66(4):1102-1110. PubMed ID: 28543053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
    Murray KF; Balistreri WF; Bansal S; Whitworth S; Evans HM; Gonzalez-Peralta RP; Wen J; Massetto B; Kersey K; Shao J; Garrison KL; Parhy B; Brainard DM; Arnon R; Gillis LA; Jonas MM; Lin CH; Narkewicz MR; Schwarz K; Rosenthal P
    Hepatology; 2018 Dec; 68(6):2158-2166. PubMed ID: 30070726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.
    Ho SB; Monto A; Peyton A; Kaplan DE; Byrne S; Moon S; Copans A; Rossaro L; Roy A; Le H; Dvory-Sobol H; Zhu Y; Brainard DM; Guyer W; Shaikh O; Fuchs M; Morgan TR;
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):282-288. PubMed ID: 27237429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.
    Rosenthal P; Schwarz KB; Gonzalez-Peralta RP; Lin CH; Kelly DA; Nightingale S; Balistreri WF; Bansal S; Jonas MM; Massetto B; Brainard DM; Hsueh CH; Shao J; Parhy B; Davison S; Feiterna-Sperling C; Gillis LA; Indolfi G; Sokal EM; Murray KF; Wirth S
    Hepatology; 2020 Jan; 71(1):31-43. PubMed ID: 31222783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.
    Balistreri WF; Murray KF; Rosenthal P; Bansal S; Lin CH; Kersey K; Massetto B; Zhu Y; Kanwar B; German P; Svarovskaia E; Brainard DM; Wen J; Gonzalez-Peralta RP; Jonas MM; Schwarz K
    Hepatology; 2017 Aug; 66(2):371-378. PubMed ID: 27997679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
    Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
    Lawitz E; Matusow G; DeJesus E; Yoshida EM; Felizarta F; Ghalib R; Godofsky E; Herring RW; Poleynard G; Sheikh A; Tobias H; Kugelmas M; Kalmeijer R; Peeters M; Lenz O; Fevery B; De La Rosa G; Scott J; Sinha R; Witek J
    Hepatology; 2016 Aug; 64(2):360-9. PubMed ID: 26704148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A phase II, single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of sofosbuvir combined with ribavirin in patients with genotype 2 chronic hepatitis C virus infection].
    Gao YH; Li GM; Jin QL; Zhao YR; Jia ZS; Mao XR; Yang YF; Shang J; Wang GC; Xie W; Wu SM; Zhang MX; Hou JL; Li DL; Nan YM; Guan YJ; Zhu CX; Yuan YZ; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):352-357. PubMed ID: 31177659
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gane EJ; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CAM
    Gastroenterology; 2017 May; 152(6):1366-1371. PubMed ID: 28137593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.
    Kim YM; Kim SB; Song IH; Lee SH; Kim HS; Lee TH; Kang YW; Kim SH; Lee BS; Chae HB; Song MJ; Jang JW; Ko SY; Lee JD
    Clin Mol Hepatol; 2018 Sep; 24(3):311-318. PubMed ID: 29865774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
    Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
    Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
    Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
    Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
    Gane EJ; Shiffman ML; Etzkorn K; Morelli G; Stedman CAM; Davis MN; Hinestrosa F; Dvory-Sobol H; Huang KC; Osinusi A; McNally J; Brainard DM; McHutchison JG; Thompson AJ; Sulkowski MS;
    Hepatology; 2017 Oct; 66(4):1083-1089. PubMed ID: 28498551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real-world setting?
    Yoon JH; Jun CH; Seo JH; Cho HA; Cho SB; Choi SK; Cho JY; Kim MW; Lim SW
    J Dig Dis; 2019 Jan; 20(1):31-37. PubMed ID: 30548199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
    Izumi N; Takehara T; Chayama K; Yatsuhashi H; Takaguchi K; Ide T; Kurosaki M; Ueno Y; Toyoda H; Kakizaki S; Tanaka Y; Kawakami Y; Enomoto H; Ikeda F; Jiang D; De-Oertel S; McNabb BL; Camus G; Stamm LM; Brainard DM; McHutchison JG; Mochida S; Mizokami M
    Hepatol Int; 2018 Jul; 12(4):356-367. PubMed ID: 30030720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
    Shah SR; Chowdhury A; Mehta R; Kapoor D; Duseja A; Koshy A; Shukla A; Sood A; Madan K; Sud R; Nijhawan S; Pawan R; Prasad M; Kersey K; Jiang D; Svarovskaia E; Doehle B; Kanwar B; Subramanian M; Acharya SK; Sarin S
    J Viral Hepat; 2017 May; 24(5):371-379. PubMed ID: 27933698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
    Jacobson IM; Gordon SC; Kowdley KV; Yoshida EM; Rodriguez-Torres M; Sulkowski MS; Shiffman ML; Lawitz E; Everson G; Bennett M; Schiff E; Al-Assi MT; Subramanian GM; An D; Lin M; McNally J; Brainard D; Symonds WT; McHutchison JG; Patel K; Feld J; Pianko S; Nelson DR; ;
    N Engl J Med; 2013 May; 368(20):1867-77. PubMed ID: 23607593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.